The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its effectiveness
Zubair et al.
, The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its..
, Monaldi Archives for Chest Disease, doi:10.4081/monaldi.2022.2062
Retrospective 188 hospitalized patients in Pakistan, 90 treated with ivermectin, showing no significant differences with treatment. The ivermectin group had more severe disease (66% vs 58%, with 6x higher risk for severe disease patients), and more male patients (70% vs. 65%). Higher use of remdesivir and steroids in the ivermectin group also suggests that ivermectin was more likely to be given to patients in more severe condition. There were no side effects seen with ivermectin. Authors note that significantly improved ferritin levels were seen with treatment. Authors state that ivermectin patients received 2 12mg doses, 24 hours apart, but later state that the dosage was not standardized.
This study is excluded in the after exclusion results of meta
substantial unadjusted confounding by indication
likely; unadjusted results with no group details.
risk of death, 9.0% higher, RR 1.09, p = 1.00, treatment 5 of 90 (5.6%), control 5 of 98 (5.1%), unadjusted.
hospitalization time, 8.0% higher, relative time 1.08, p = 0.40, treatment 90, control 98, unadjusted, Table 3, mean number of days.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zubair et al., 18 Jan 2022, retrospective, Pakistan, peer-reviewed, 8 authors, study period October 2020 - February 2021, dosage 12mg single dose.
Abstract: Monaldi Archives for Chest Disease
Publisher's Disclaimer. E-publishing ahead of print is increasingly important for the rapid
dissemination of science. The Monaldi Archives for Chest Disease is, therefore, Epublishing PDF files of an early version of manuscripts that undergone a regular peer
review and have been accepted for publication, but have not been through the
copyediting, typesetting, pagination and proofreading processes, which may lead to
differences between this version and the final one.
The final version of the manuscript will then appear on a regular issue of the journal.
E-publishing of this PDF file has been approved by the authors.
Monaldi Arch Chest Dis 2022 [Online ahead of print]
To cite this Article:
Zubair SM, Chaudhry MW, Zubairi ABS, et al. The effect of ivermectin on non-severe
and severe COVID-19 disease and gender-based difference of its effectiveness.
Monaldi Arch Chest Dis
© the Author(s), 2022
Licensee PAGEPress, Italy
Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any
queries should be directed to the corresponding author for the article.
The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based
difference of its effectiveness
Syed Muhammad Zubair, Muhammad Waleed Chaudhry, Ali Bin Sarwar Zubairi,
Talha Shahzad, Aqusa Zahid, Ibrahim Ali Khan, Javaid Ahmed Khan, Muhammad Irfan
Section of Pulmonary Medicine, Department of Medicine Aga Khan University Hospital,
Corresponding Author: Muhammad Irfan, Professor, Section of Pulmonary Medicine,
Department of Medicine Aga Khan University Hospital, Karachi, Pakistan. Address: Faculty
Office Building, National Stadium Road, Aga Khan University Hospital, Karachi, Karachi City,
Sindh 74800. Phone: 02134864664 - Cell phone: +923002111459
i) Authors Contribution:
1) Syed Muhammad Zubair: Data Collection, statistical analysis, literature review,
2) Muhammad Waleed Chaudhry: Data Collection, statistical analysis, literature review,
3) Ali Bin Sarwar Zubairi: Wrote, reviewed and edited the manuscript.
4) Talha Shahzad: Reviewed and edited the manuscript.
5) Aqusa Zahid: Data Collection, reviewed and edited the manuscript.
6) Ibrahim Ali Khan: Reviewed and edited the manuscript.
7) Javaid Ahmed Khan: Reviewed and edited the manuscript.
8) Muhammad Irfan: Conceived the idea, wrote, reviewed and edited the manuscript.
Ethics approval: The study protocol was approved by the Ethics Review Committee (ERC) of the
Aga Khan University Hospital (Application no: 2021-5902-16610).
ii) There is no conflict of interests.
iii) There is no funding for this article. The abstract of this article has been scheduled to be
presented at the following forum:
1) Abstract title: Role of ivermectin in hospitalized patients with mild to moderate
COVID-19. To be presented as an ‘e-poster’ at virtual European Respiratory
Society Congress 2021 on 07-09-2021.
The COVID-19 pandemic has led to mortality and morbidity since December 2019. Many possible
treatment options have been advised till date. The role of ivermectin in the treatment of COVID19 disease remains controversial. The aim of our study was to evaluate the effect of ivermectin in
hospitalized patients with non-severe and severe..
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.